CSL ‘cautious’ on profit outlook even after vaccines boosted half-year results – Sydney Morning Herald

The full-year result will be heavily skewed to the first half, he told analysts. The impacts of COVID, both positive and negative, add a pretty heavy layer of complexity and uncertainty to our earnings profile until we get through this pandemic.
CSL maintained its previous earnings guidance, predicting profits of between $2.17 and $2.27 billion for the 2021 financial year. Asked why the $131 billion biotech wasnt increasing its forecasts, Mr Perreault highlighted that because of the seasonal nature…

Click here to view the original article.